Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1127283

registered interest
date	17/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage fairer pricing by pharmaceutical companies for drugs supplied to the NHS.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	255651
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The 2019 Voluntary Scheme for Branded Medicines Pricing and Access, and the statutory scheme for branded medicines pricing, work together to control the cost of branded medicines to the National Health Service and ensure it stays within affordable limits.</p><p> </p><p>The 2019 Voluntary Scheme began on 1 January 2019 and will run for five years until the end of 2023. The Voluntary Scheme aims to provide stability and predictability for all parties in terms of the United Kingdom’s branded medicines expenditure and the medicines pricing and access environment for the period 2019 to 2023. It also aims to achieve a balance between patient access, affordability and supporting the development of innovative new medicines, including support for small companies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:30:06 answering member 4455 label Biography information for Seema Kennedy
tabling member	308 label Biography information for Mr Jim Cunningham

1127327

registered interest
date	17/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diffuse Intrinsic Pontine Glioma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of access to NHS support for sufferers of diffuse intrinsic pontine glioma.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	255692
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>No specific assessment has been made by the Department at this time.</p><p>Care for children with Diffuse Intrinsic Pontine Glioma (DIPG) is co-ordinated and provided by Children’s Cancer Principal Treatment Centres (PTCs) working in conjunction with Paediatric Oncology Shared Care Units. Children’s Cancer PTCs are responsible for planning and delivering treatment for children with DIPG as well as ensuring these children can access wider support services such as psychology services, specialist play services and other therapies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:25:19 answering member 4455 label Biography information for Seema Kennedy
tabling member	4571 label Biography information for Gill Furniss